Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Triple Negative Breast Neoplasms 1Skin Neoplasms 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Specimen Handling 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Melanoma × Toll-Like Receptor 1 × Clear all
NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
13 enrolled 10 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT03374839 2022-05-06

Nivo-TIL

Nantes University Hospital

Phase 1/2 Unknown
11 enrolled
Dermatologic

Melanoma

NCT00200577 2017-06-01

TIL

Nantes University Hospital

Phase 3 Completed
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡